These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 15604516

  • 1. Dual-action hypoglycemic and hypocholesterolemic agents that inhibit glycogen phosphorylase and lanosterol demethylase.
    Harwood HJ, Petras SF, Hoover DJ, Mankowski DC, Soliman VF, Sugarman ED, Hulin B, Kwon Y, Gibbs EM, Mayne JT, Treadway JL.
    J Lipid Res; 2005 Mar; 46(3):547-63. PubMed ID: 15604516
    [Abstract] [Full Text] [Related]

  • 2. Novel cholesterol biosynthesis inhibitors targeting human lanosterol 14alpha-demethylase (CYP51).
    Korosec T, Acimovic J, Seliskar M, Kocjan D, Tacer KF, Rozman D, Urleb U.
    Bioorg Med Chem; 2008 Jan 01; 16(1):209-21. PubMed ID: 17964172
    [Abstract] [Full Text] [Related]

  • 3. Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo.
    Martin WH, Hoover DJ, Armento SJ, Stock IA, McPherson RK, Danley DE, Stevenson RW, Barrett EJ, Treadway JL.
    Proc Natl Acad Sci U S A; 1998 Feb 17; 95(4):1776-81. PubMed ID: 9465093
    [Abstract] [Full Text] [Related]

  • 4. Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.
    Walker KA, Kertesz DJ, Rotstein DM, Swinney DC, Berry PW, So OY, Webb AS, Watson DM, Mak AY, Burton PM.
    J Med Chem; 1993 Jul 23; 36(15):2235-7. PubMed ID: 8340925
    [No Abstract] [Full Text] [Related]

  • 5. Lanosterol analogs: dual-action inhibitors of cholesterol biosynthesis.
    Frye LL, Leonard DA.
    Crit Rev Biochem Mol Biol; 1999 Jul 23; 34(2):123-40. PubMed ID: 10333389
    [Abstract] [Full Text] [Related]

  • 6. Synthesis, in vitro ADME profiling and in vivo pharmacological evaluation of novel glycogen phosphorylase inhibitors.
    Miao GX, Wang YD, Yan ZW, Zhang LY.
    Bioorg Med Chem Lett; 2020 Jul 15; 30(14):127117. PubMed ID: 32527535
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics and anti-hyperglycaemic efficacy of a novel inhibitor of glycogen phosphorylase, 1,4-dideoxy-1,4-imino-d- arabinitol, in glucagon-challenged rats and dogs and in diabetic ob/ob mice.
    Mackay P, Ynddal L, Andersen JV, McCormack JG.
    Diabetes Obes Metab; 2003 Nov 15; 5(6):397-407. PubMed ID: 14617225
    [Abstract] [Full Text] [Related]

  • 8. Selective inhibition of mammalian lanosterol 14 alpha-demethylase by RS-21607 in vitro and in vivo.
    Swinney DC, So OY, Watson DM, Berry PW, Webb AS, Kertesz DJ, Shelton EJ, Burton PM, Walker KA.
    Biochemistry; 1994 Apr 19; 33(15):4702-13. PubMed ID: 8161528
    [Abstract] [Full Text] [Related]

  • 9. Azalanstat (RS-21607), a lanosterol 14 alpha-demethylase inhibitor with cholesterol-lowering activity.
    Burton PM, Swinney DC, Heller R, Dunlap B, Chiou M, Malonzo E, Haller J, Walker KA, Salari A, Murakami S.
    Biochem Pharmacol; 1995 Aug 08; 50(4):529-44. PubMed ID: 7646560
    [Abstract] [Full Text] [Related]

  • 10. Effect of 26-oxygenosterols from Ganoderma lucidum and their activity as cholesterol synthesis inhibitors.
    Hajjaj H, Macé C, Roberts M, Niederberger P, Fay LB.
    Appl Environ Microbiol; 2005 Jul 08; 71(7):3653-8. PubMed ID: 16000773
    [Abstract] [Full Text] [Related]

  • 11. The effect of glucose on the potency of two distinct glycogen phosphorylase inhibitors.
    Andersen B, Westergaard N.
    Biochem J; 2002 Oct 15; 367(Pt 2):443-50. PubMed ID: 12099891
    [Abstract] [Full Text] [Related]

  • 12. Lanosterol 14 alpha-demethylase (P45014DM): effects of P45014DM inhibitors on sterol biosynthesis downstream of lanosterol.
    Tuck SF, Patel H, Safi E, Robinson CH.
    J Lipid Res; 1991 Jun 15; 32(6):893-902. PubMed ID: 1940622
    [Abstract] [Full Text] [Related]

  • 13. Design, synthesis, and pharmacological evaluation of N-bicyclo-5-chloro-1H-indole-2-carboxamide derivatives as potent glycogen phosphorylase inhibitors.
    Onda K, Shiraki R, Ogiyama T, Yokoyama K, Momose K, Katayama N, Orita M, Yamaguchi T, Furutani M, Hamada N, Takeuchi M, Okada M, Ohta M, Tsukamoto S.
    Bioorg Med Chem; 2008 Dec 01; 16(23):10001-12. PubMed ID: 18952447
    [Abstract] [Full Text] [Related]

  • 14. Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase.
    Hoover DJ, Lefkowitz-Snow S, Burgess-Henry JL, Martin WH, Armento SJ, Stock IA, McPherson RK, Genereux PE, Gibbs EM, Treadway JL.
    J Med Chem; 1998 Jul 30; 41(16):2934-8. PubMed ID: 9685232
    [No Abstract] [Full Text] [Related]

  • 15. Cholesterol biosynthesis from lanosterol: differential inhibition of sterol delta 8-isomerase and other lanosterol-converting enzymes by tamoxifen.
    Cho SY, Kim JH, Paik YK.
    Mol Cells; 1998 Apr 30; 8(2):233-9. PubMed ID: 9638657
    [Abstract] [Full Text] [Related]

  • 16. Biochemical basis for a cholesterol-lowering activity of 2-[2"-(1",3"-dioxolane)]-2-methyl-4-(2'-oxo-1'-pyrrolidinyl)-6- nitro-2H-1-benzopyran (SKP-450), a novel antihypertensive agent.
    Lee EY, Lim DM, Yoo SE, Kim DK, Paik YK.
    Biochem Pharmacol; 1999 Mar 01; 57(5):579-82. PubMed ID: 9952322
    [Abstract] [Full Text] [Related]

  • 17. Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors.
    Ekins S, Mankowski DC, Hoover DJ, Lawton MP, Treadway JL, Harwood HJ.
    Drug Metab Dispos; 2007 Mar 01; 35(3):493-500. PubMed ID: 17194716
    [Abstract] [Full Text] [Related]

  • 18. Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition.
    Goyard D, Kónya B, Chajistamatiou AS, Chrysina ED, Leroy J, Balzarin S, Tournier M, Tousch D, Petit P, Duret C, Maurel P, Somsák L, Docsa T, Gergely P, Praly JP, Azay-Milhau J, Vidal S.
    Eur J Med Chem; 2016 Jan 27; 108():444-454. PubMed ID: 26708111
    [Abstract] [Full Text] [Related]

  • 19. Silencing of mouse hepatic lanosterol 14-alpha demethylase down-regulated plasma low-density lipoprotein cholesterol levels by short-term treatment of siRNA.
    Xu B, Wang C, Yang J, Mao G, Zhang C, Liu D, Tai P, Zhou B, Xia G, Zhang M.
    Biol Pharm Bull; 2008 Jun 27; 31(6):1182-91. PubMed ID: 18520052
    [Abstract] [Full Text] [Related]

  • 20. Modulation of 3-hydroxy-3-methylglutaryl-CoA reductase by 15 alpha-fluorolanost-7-en-3 beta-ol. A mechanism-based inhibitor of cholesterol biosynthesis.
    Trzaskos JM, Magolda RL, Favata MF, Fischer RT, Johnson PR, Chen HW, Ko SS, Leonard DA, Gaylor JL.
    J Biol Chem; 1993 Oct 25; 268(30):22591-9. PubMed ID: 7693673
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.